Methods
We conducted a qualitative descriptive study to explore MM patients’ diagnostic journeys. We utilized a community advisory board (CAB) to advise our research program. Our CAB included three community partners who are survivors of MM (authors TG, TN, and VT) whose own diagnosis stories inspired the focus of this study. The CAB contributed to study conceptualization, development of the interview guide, staff training and participated in the interpretation and dissemination of study findings. Study approval was obtained from the University of North Carolina at Chapel Hill Institutional Review Board (IRB# 24-0018).
Participants were recruited through an academic medical center in the Southeastern United States from community health fairs, an online institutional research portal, an outpatient oncology clinic, and through community partnerships. Eligible participants were adults (≥18 years), spoke English and/or Spanish and had been diagnosed with MM within the past 10 years. Participants were purposively sampled to ensure racial and ethnic diversity (Hispanic, African American/Black, Other).
Patients were approached to explain study goals and procedures, assess interest in participating, assess eligibility and schedule interviews. Interviews were conducted by trained research staff (MRL an assistant professor, and research assistants ML, and KB, both masters of public health students) between October 2024 and June 2025 via telephone or videoconference platform. Verbal consent (IRB approved) was obtained from MM patient participants and their family/care partners if patients choose to include them in the interview. Patient demographic characteristics were collected using a short survey. Interviews were conducted in English or Spanish, audio-recorded, and transcribed by a professional, multilingual transcription service (Landmark Associates). Participants received a $45 gift card incentive for participation.
The health care access framework Model of Pathways to Treatment (MPT) helped guide the development of our semi-structured interview guide. 15 , 16 Our guide was also informed by the work of Asad and colleagues, who investigated multilevel determinants of endometrial cancer diagnosis who graciously allowed us to reference their interview guide.
17
Briefly the MPT proposes that patients will experience a series of events and processes as they move through the several intervals on their way to treatment ( Figure 1 ). 15 , 16 Our study explores the process of moving through the first three of these intervals (Appraisal, Help Seeking, Diagnostic) which culminate in a person receiving their MM diagnosis. Figure 1. Model of pathways to treatment adapted from Walter et al. (2012)
15
to highlight the Appraisal, Help-seeking and Diagnostic intervals. HCP: health care provider Multiple myeloma: Insights into a challenging diagnostic journey
Model of pathways to treatment adapted from Walter et al. (2012)
15
to highlight the Appraisal, Help-seeking and Diagnostic intervals. HCP: health care provider
Multiple myeloma: Insights into a challenging diagnostic journey
We developed and pilot tested our interview guide (see supplemental material) with our MM CAB. Interview questions explored patient experiences with symptoms and physical changes before their MM diagnosis, the process of seeking care, and details of their encounters with the health care system. We explored challenges patients faced and factors that helped facilitate their MM diagnosis. Study materials were initially drafted in English then translated into Spanish by our bilingual and bicultural study team members. Spanish language translations were then back translated to assess accuracy and cultural congruence.
Transcripts were analyzed using thematic reflexive analysis in Atlas.ti (version 25.0.2 for Mac; Scientific Software Development GmbH). All transcripts were analyzed in English-language and read in entirety by the research team. Our initial coding scheme was developed using open coding by two coders (author initials ML, KB), and a researcher (LNM) with expertise in qualitative methods. They initially reviewed five transcripts to establish the coding scheme by comparing and validating emerging codes and developing a preliminary codebook. After completing code checking and validation, the codebook was revised through an iterative code–recode approach, with coders reaching consensus through discussion. Discrepancies were resolved by a third coder. Analytic memos documented emerging reflections and insights from the coding process. Codes were grouped into categories using concepts from the Models of Pathways to Treatment.
15
We used the framework’s definition of key constructs and concepts to define categories and then categorized codes based relationships that emerged. Themes were reviewed and refined through group discussion to identify patterns and inconsistencies across interviews. Triangulation was achieved by reviewing analytic memos, having iterative discussion with study team members, and sharing preliminary findings with our CAB to validate perspectives. Data collection and analysis proceeded iteratively until thematic saturation was reached, defined as the point at which no new themes, concepts, or insights emerged from successive interviews.
Results
34 participants were interviewed, 13 (38.2%) were Black/African American, 7 (20.6%), Hispanic/Latino, 12 (35.3%) White, and 2 (5.9%) Asian. The median age of participants was 70.5 (range 46 – 95) years old. Just over half were female (52.9%) and a majority were married/partnered (73.5%). A plurality reported having private insurance (44.1%), and 5 (14.7%) reported no insurance at diagnosis ( Table 1 ). Interviews lasted a median of 48 minutes with an interquartile range of 42.25 to 56.75 minutes. Because our recruitment strategies included passive methods (e.g., research portal), quantifying the number who considered and then refused participation was not possible. Among those directly approached for participation 8 who were eligible ultimately did not participate in the study. Table 1. Participant characteristics (n = 34) n (%) Age in years at interview median (IQR) 70.5 (60 – 76) Years since diagnosis median (IQR) 2.8 (1.8 – 4.7) Sex Male 16 (47.1) Female 18 (52.9) Race NH Black/African American 13 (38.2) NH White 12 (35.3) Asian 2 (5.9) Hispanic/Latino 7 (20.6) Insurance at diagnosis None 5 (14.7) Medicaid, any 3 (8.8) Medicare, only 8 (23.5) Private, any 15 (44.1) Other 3 (8.8) Partnered status Married/partnered 25 (73.5) Never married 2 (5.9) Separated/divorced 4 (11.8) Widowed 3 (8.8) Income $0 - $30,000 7 (20.6) $31,000 - $60,000 8 (23.5) $61,000 - $90,000 7 (20.6) $91,000 - $120,000 5 (14.7) $121,000 or more 5 (14.7) missing 2 (5.9) Education 1 - 12 years, but did not graduate 2 (5.9) Completed High School/GED 3 (8.8) Some college 9 (26.5) College graduate, 2 – year degree 3 (8.8) College graduate 4 – year degree 10 (29.4) Post graduate degree (Master's, Doctorate) 7 (20.6)
Participant characteristics (n = 34)
Our analysis uncovered factors that facilitated patients to quickly receive a MM diagnosis and factors that were barriers and delayed the diagnostic process. Relevant themes and subthemes are presented below.
Arriving at a MM diagnosis often began with a person noticing changes in their body or their functional capacity and being concerned enough to escalate from self-care to seeking help from a health care provider. Once in care the MM diagnostic process only advanced when concern over a person’s signs and symptoms escalated enough for providers to explore less common, and more concerning causes like cancer. A thread in many participants’ diagnosis stories was the presence of someone (e.g., themselves, family/friend, healthcare provider) who recognized changes that concerned them enough to advocate for further action.
1a. Recognizing Health Changes and Deciding to Seek Initial Care.
During the help-seeking interval, when patients were assessing whether and how to seek care, patients reported that family, friends/coworkers played critical roles in recognizing changes in a person and encouraging them to seek care they may not have otherwise. “Well, my husband, my kids would always say, “You need to go to the doctor.” I said, “Oh, hey, it's going to go away, it's just the workload.” I think I spent more times with my coworkers, and they saw the change. When I would get up, I would walk, I had my hand on my back, I'm, like, “Oh, it is bothering me.” They pushed me to get an appointment, actually. That's when I went to an orthopedic clinic.” [46-year-old female] “ […] my family knew. They saw how I was walking and all that, so that’s why they encouraged me to go be seen by a doctor instead of dealing with it.” [64-year-old female]
“Well, my husband, my kids would always say, “You need to go to the doctor.” I said, “Oh, hey, it's going to go away, it's just the workload.” I think I spent more times with my coworkers, and they saw the change. When I would get up, I would walk, I had my hand on my back, I'm, like, “Oh, it is bothering me.” They pushed me to get an appointment, actually. That's when I went to an orthopedic clinic.” [46-year-old female]
“ […] my family knew. They saw how I was walking and all that, so that’s why they encouraged me to go be seen by a doctor instead of dealing with it.” [64-year-old female]
1b. Advocacy as a Catalyst for Care Escalation.
For several participants, care was only escalated after repeated, unsuccessful attempts to address concerning symptoms. Advocacy and persistence by the patient and/or their families was not only a facilitator but often a crucial turning point in moving toward diagnostic resolution. “I was experiencing some pain from my lower back just above my buttocks, to my bottom of my pelvis. Down my legs. I went back to him again and kept complaining. I'm telling you this, it was about for complaining about two or three visits. He didn't understand that. He sent me to get an MRI.” [71-year-old male]
“I was experiencing some pain from my lower back just above my buttocks, to my bottom of my pelvis. Down my legs. I went back to him again and kept complaining. I'm telling you this, it was about for complaining about two or three visits. He didn't understand that. He sent me to get an MRI.” [71-year-old male]
1c. Logistical barriers to care.
Lack of access to primary care complicated the journeys of several participants for seven participants, of which 5 did not have insurance at the time of diagnosis. For two participants who had insurance but could not get appointments with their primary care providers, they relied on urgent care for symptom management. For both, symptoms worsened dramatically and they ended up in the emergency department. “The two-week, three-week delay, that was when I was throwin' up. Again, if I couldn't see her today, I needed to find somebody I could see today, because it's not getting better.” [60-year-old female] “Went back to the urgent care, 'cause my primary care posi—she's a nurse practitioner. She was actually on vacation, and so at her office, she's the only one in the office, so I had no one else really to go to. I just went back to the convenience care and where they gave me the Augmentin and still didn't really get better.” [57-year-old female]
“The two-week, three-week delay, that was when I was throwin' up. Again, if I couldn't see her today, I needed to find somebody I could see today, because it's not getting better.” [60-year-old female]
“Went back to the urgent care, 'cause my primary care posi—she's a nurse practitioner. She was actually on vacation, and so at her office, she's the only one in the office, so I had no one else really to go to. I just went back to the convenience care and where they gave me the Augmentin and still didn't really get better.” [57-year-old female]
Among the hand full of participants without insurance care was complicated and fragmented. He said, “No, you're entitled to this and this. You're not entitled to that. You have to do that with your insurance.” I didn't have insurance. [76 year-old male] “I would have liked to have a family doctor, a family doctor that could do tests. But you know that now, back then you couldn’t [without] insurance.” [54-year-old female]
He said, “No, you're entitled to this and this. You're not entitled to that. You have to do that with your insurance.” I didn't have insurance. [76 year-old male]
“I would have liked to have a family doctor, a family doctor that could do tests. But you know that now, back then you couldn’t [without] insurance.” [54-year-old female]
2a. Providers Recognize Changes and Escalate Care.
Most participants reported that health care providers played critical roles in raising concerns about health changes or concerning findings after abnormal lab or imaging results which led to outpatient oncology referrals and MM diagnosis. “Then when I talked to her later, she said, “Well I want you to come and get your blood tested.” I did that and she called me that night and said, “Your blood work is—” I don't know what the word she used, “but you're very anemic and your blood is really not good.” I don't remember. She called my breast cancer team and told them that that I was having all that problem and it wasn't just my age that was making me be so tired all the time.” [82-year-old female]
“Then when I talked to her later, she said, “Well I want you to come and get your blood tested.” I did that and she called me that night and said, “Your blood work is—” I don't know what the word she used, “but you're very anemic and your blood is really not good.” I don't remember. She called my breast cancer team and told them that that I was having all that problem and it wasn't just my age that was making me be so tired all the time.” [82-year-old female]
Prior provider relationships helped clinicians identify concerning changes from a patient’s “normal”. “The kidney specialist, he was fine with me coming back looking at him every six months, but she [primary care provider] was the one that said, ‘I still don’t like it.’ Then she said, ‘You don’t have to, but I think it would be good ’cause they can run tests that nobody else can run.’ That’s when I went.” [71-year-old female]
“The kidney specialist, he was fine with me coming back looking at him every six months, but she [primary care provider] was the one that said, ‘I still don’t like it.’ Then she said, ‘You don’t have to, but I think it would be good ’cause they can run tests that nobody else can run.’ That’s when I went.” [71-year-old female]
2b. Routine Care as a Pathway to Early Detection . Established, routine care was an important factor in many diagnosis stories. These included six participants who presented for routine wellness check-ups (e.g. annual physicals), and four who’s diagnostic journey included appointments related to managing preexisting comorbidities, like diabetes or even a MM precursor condition like smoldering MM. The extra attention and more extensive surveillance that come along with managing chronic diseases helped some participants move swiftly towards their MM diagnosis. For example, this participant was seeing their PCP every three months to manage their Type 2 diabetes.
“It was maybe November the 4th or 5th I went to see my primary care physician, and he did order a 24-hour urine sample. I took that back on that Friday and then on that Monday I was goin' over all of my test results and I was like, “Whoa, wait a minute.” Because the creatinine was in the red, high. I called my doctor. Actually, I called him on that Friday and left him a message, but he I guess didn't get to the results until Monday. Tuesday morning he called me and said, “Hey, I need you to go to the hospital right now 'cause your creatinine is 7.57” [62-year-old female]
“It was maybe November the 4th or 5th I went to see my primary care physician, and he did order a 24-hour urine sample. I took that back on that Friday and then on that Monday I was goin' over all of my test results and I was like, “Whoa, wait a minute.” Because the creatinine was in the red, high. I called my doctor. Actually, I called him on that Friday and left him a message, but he I guess didn't get to the results until Monday. Tuesday morning he called me and said, “Hey, I need you to go to the hospital right now 'cause your creatinine is 7.57” [62-year-old female]
For this participant, a diagnosis of smoldering MM was made when they were switching PCPs, which led to consistent surveillance and an early recognition of MM through changing lab results.
“…they were not doing any active treatment while smoldering. They would watch it. Then I had to get periodic blood tests every several months. Then towards the end of, I would say, 2019, they started noticing the bloodwork was showing a more active myeloma process.” [86-year-old female]
“…they were not doing any active treatment while smoldering. They would watch it. Then I had to get periodic blood tests every several months. Then towards the end of, I would say, 2019, they started noticing the bloodwork was showing a more active myeloma process.” [86-year-old female]
Prearranged annual physical examinations provided a shortcut around the appraisal and help-seeking intervals of the diagnostic process. Annual physicals facilitated diagnoses when participants had noticed changes but had not recognized them as issues warranting medical attention. “I’d feel a little short of breath, which I had never felt before on that same walk. I just write it all off to aging, figuring, ‘Okay, well’—at that time I was 79. I’m thinking, ’Well, I guess maybe it’s part of aging.’ I didn’t worry about it too much. I just wrote it off. In July, around the first – end of the first week/beginning of the second week of July, I had my annual physical checkup with my general practitioner, Dr. […]. I felt fine. I didn’t report anything to her, but the regular CBC, the blood test, came back and showed that my hemoglobin and red blood cell count was low . ” [82-year-old male]
“I’d feel a little short of breath, which I had never felt before on that same walk. I just write it all off to aging, figuring, ‘Okay, well’—at that time I was 79. I’m thinking, ’Well, I guess maybe it’s part of aging.’ I didn’t worry about it too much. I just wrote it off. In July, around the first – end of the first week/beginning of the second week of July, I had my annual physical checkup with my general practitioner, Dr. […]. I felt fine. I didn’t report anything to her, but the regular CBC, the blood test, came back and showed that my hemoglobin and red blood cell count was low . ” [82-year-old male]
Routine primary care physicals could also serve as a safety net for those resistant to seeking care otherwise.
“Originally it was from like February of '21 till September that he was having these little—his pains and his issues. Getting him to go to the doctor it's like delivering quadruplets or something, he won't go. That's why he didn't go till September for his physical.” [Caregiver for 70-year-old male]
“Originally it was from like February of '21 till September that he was having these little—his pains and his issues. Getting him to go to the doctor it's like delivering quadruplets or something, he won't go. That's why he didn't go till September for his physical.” [Caregiver for 70-year-old male]
In other cases (6), participants were entirely asymptomatic and suspicion was raised through incidental lab findings.
“… she went to get a yearly checkup early April. They found that something in her kidneys was abnormal.” [caregiver for a 76-year-old female]
“… she went to get a yearly checkup early April. They found that something in her kidneys was abnormal.” [caregiver for a 76-year-old female]
Misattribution of MM related symptoms to other less concerning conditions, on the part of the person or their health care providers, delayed the escalation of care needed to arrive at a MM diagnosis. Escalation often only occurred when symptoms worsened to the point of needing urgent attention.
3a. Patients’ Minimizing Symptoms as Normal Aging or Other Less Concerning Conditions.
Half of participants often dismissed their symptoms as part of age-related changes or attributed them to other less concerning conditions. This delayed care seeking and/or escalation of care. “I noticed when I was walking my dog, if we […] started walking up a couple sharp hills on our walk, I’d feel a little short of breath, which I had never felt before on that same walk. I just write it all off to aging, figuring, ‘Okay, well’—at that time I was 79. I’m thinking, ‘Well, I guess maybe it’s part of aging.’” [82-year-old male]
“I noticed when I was walking my dog, if we […] started walking up a couple sharp hills on our walk, I’d feel a little short of breath, which I had never felt before on that same walk. I just write it all off to aging, figuring, ‘Okay, well’—at that time I was 79. I’m thinking, ‘Well, I guess maybe it’s part of aging.’” [82-year-old male]
3b. Providers’ Misdiagnoses of Presenting Symptoms Led to Reduced Urgency for Care Escalation.
Providers, understandably, appeared to attribute MM symptoms to more common less concerning conditions prolonging conservative management and delaying MM diagnosis. For four participants, lack of improvement with conservative management led to care escalation and outpatient diagnosis, and for eight others misdirected management persisted until an acute event compelled escalation of care. “I did physical therapy probably for about four months, and it was getting—it wasn't getting any better and I was hurting. It was like they would lift my leg up and they would do that. They'd be hurting so bad and I'd be like, ‘What in the world?’” [68-year-old female] “I had a back pain for almost a year. I was getting treatments for back pain, like I would go to PT, I got a couple SI [sacroiliac] joint injections because that's what they were thinking my pain was coming from, my SI joint, because it was very close to my hip bone. That's what was happening, never in a million years thought that it could be something different. I had a traumatic fall in December of 2022. I remember the day, December 26th was my fall, and that's when I figured something was really wrong. Went to the hospital, when they did the CTs and MRIs, that's where they found out I had a huge tumor in my acetabular area, which caused the break and the fall.” [46-year-old female]
“I did physical therapy probably for about four months, and it was getting—it wasn't getting any better and I was hurting. It was like they would lift my leg up and they would do that. They'd be hurting so bad and I'd be like, ‘What in the world?’” [68-year-old female]
“I had a back pain for almost a year. I was getting treatments for back pain, like I would go to PT, I got a couple SI [sacroiliac] joint injections because that's what they were thinking my pain was coming from, my SI joint, because it was very close to my hip bone. That's what was happening, never in a million years thought that it could be something different. I had a traumatic fall in December of 2022. I remember the day, December 26th was my fall, and that's when I figured something was really wrong. Went to the hospital, when they did the CTs and MRIs, that's where they found out I had a huge tumor in my acetabular area, which caused the break and the fall.” [46-year-old female]
Cancer was never suspected by our participants which hindered more efficient diagnostic journeys. Three in four participants reported not knowing anything about MM before their diagnosis.
“Interviewer: Back then, what did you know about multiple myeloma?
Interviewee: Actually, I knew nothing. [77-year-old male] “I never heard of it and when I mentioned it to people, people assume right away that it was skin cancer. I said no. The word’s spelled and pronounced differently, so skin cancer, it’s not skin cancer. It’s a blood cancer.” [64-year-old female]
“Interviewer: Back then, what did you know about multiple myeloma?
Interviewee: Actually, I knew nothing. [77-year-old male]
“I never heard of it and when I mentioned it to people, people assume right away that it was skin cancer. I said no. The word’s spelled and pronounced differently, so skin cancer, it’s not skin cancer. It’s a blood cancer.” [64-year-old female]
Even patients that had some knowledge were mostly unfamiliar with MM. “I worked for a hospice, and I worked for it for 16 years, and I think I've had one person with multiple myeloma. I didn't really get into exactly, I knew it was cancer, of course, but I didn't know exactly what it affected.” [60-year-old female]
“I knew a little bit regarding it because my brother had been diagnosed with multiple myeloma earlier that year. Well, a year prior, I guess. Yeah, a year prior. I knew a little bit about it. I didn't know much about it.” [57-year-old male]
“I worked for a hospice, and I worked for it for 16 years, and I think I've had one person with multiple myeloma. I didn't really get into exactly, I knew it was cancer, of course, but I didn't know exactly what it affected.” [60-year-old female]
“I knew a little bit regarding it because my brother had been diagnosed with multiple myeloma earlier that year. Well, a year prior, I guess. Yeah, a year prior. I knew a little bit about it. I didn't know much about it.” [57-year-old male]
There were also indications that PCPs lacked familiarity with key clinical features indicative of possible MM. “He [provider] says to me, he said, ‘Well, you know what? Because of your test results and what happened with you,’ he said, ‘I'm able to pretty much catch multiple myeloma in other patients,’ which he's already found two to have it that he referred to hematology. Because of their creatinine levels.” [62-year-old female]
“He [provider] says to me, he said, ‘Well, you know what? Because of your test results and what happened with you,’ he said, ‘I'm able to pretty much catch multiple myeloma in other patients,’ which he's already found two to have it that he referred to hematology. Because of their creatinine levels.” [62-year-old female]
Discussion
Our findings illuminate the profound challenges faced by patients and providers in making MM diagnoses and provides guidance for improving the diagnostic process in the future. As one of only a few qualitative studies in this area our work substantially adds to our understanding of the diagnostic journey in MM. Beyond MM there are other conditions that face similar challenges (i.e., lack of recommended screening, vague non-specific symptoms and lack of awareness) such as oral cancers, ovarian cancer, endometriosis. 18 - 20 Our work may help inform an understanding for these conditions as well.
The facilitators we identified operated by promoting appropriate care escalation from self-appraisal to primary care and then to subspecialty oncologic care. We identified challenges to MM diagnosis in the appraisal, help seeking and diagnostic intervals of participants journeys.
One of the biggest challenges to timely MM diagnosis remains the non-specific nature of presenting symptoms. There are no cardinal symptoms or symptom patterns that by themselves suggest a person should be concerned they may have MM. Care must be taken when designing interventions aimed at educating the public about the signs symptoms of MM which could unnecessarily raise alarm among the many people with common symptoms resulting from less concerning conditions.
Our work highlights several key health behaviors that may be helpful. MM diagnosis in our study participants was facilitated by regular primary care utilization, and care escalation in the face of new, concerning or persistent symptoms. Promoting regular use of primary care services and teaching skills for effective self-advocacy could be helpful in improving care and increasing the likelihood that rare diseases like MM are diagnosed earlier. Primary care access challenges, including provider shortages, health care coverage gaps, and healthcare mistrust, will limit the reach of these interventions if not also addressed. 21 - 23
The axiom coined by Dr. Thomas Woodward “When you hear hooves think horses not zebras” encourages us to consider common causes before more rare ones when making diagnoses.
24
Ruling out more common causes of symptom patterns before exploring rare, less common causes, remains good advice. Many participants reported presenting with MM related symptoms and being misdiagnosed and treated for more common conditions, leading to extended delays in receiving the correct diagnosis of MM. The question remains; When patients present with the non-specific signs and symptoms of MM (pain, fatigue, anemia, kidney insufficiency, hypercalcemia, frequent infections, numbness and tingling) under what conditions should MM be considered along with more common conditions?
25
The cardinal signs and symptoms of MM are known as the CRAB criteria (hyperCalcemia, Renal insufficiency, Anemia, and Bone lesions) were commonly reported by participants preceding their diagnosis. These symptoms often did not respond to prescribed treatments (e.g., physical therapy for pain; iron supplements for anemia). When CRAB symptoms are present, persistent or worsening, further investigations should include a workup for MM. Strategies aimed at empowering patients to be strong advocates in the face of persistent or worsening symptoms, have the potential to improve care for patients with a variety of conditions, including MM.
When there is concern for MM, current recommendations for initial diagnostic workup include serum protein electrophoresis with immunofixation (SPEP w/IFE) and a serum free light chain assay (sFLC).
26
Although our data don’t allow for definitive conclusions, we suspect that there is limited awareness of MM signs and symptoms among PCPs and there is literature to suggest this is the case. Pooe et al, reported that among physicians surveyed, only 8% had received any MM education after their medical training.
27
Yagnik and colleagues report that among PCPs who had ordered an SPEP for suspected plasma cell disorder in the past year only 20% expressed confidence in knowing what tests to order if MM was suspected and in interpreting MM test results.
28
A retrospective review by Abughanimeh et al reported that only 18% of providers ordered the appropriate array of initial diagnostic tests (SPEP w/IFE, and sFLC), with IFE and sFLC frequently missed.
29
These findings highlight a substantial knowledge gap that could be targeted through education supports for PCPs.
There are several efforts from around the globe focused on improving MM diagnosis through educational programs, research into MM screening and a growing interest in the use of advanced prediction models to identify those at highest risk for MM to aid earlier detection.
Educational efforts.
Through their Early Diagnosis Steering Committee, Myeloma UK provides education to the public, general practitioners, and non-hematological specialists on the early detection of MM. Myeloma UK has developed excellent public and provider facing materials that are available on their website (myeloma.org.uk).
30
The International Myeloma Foundation (IMF) is a U.S. based organization that focuses on patient support, research, education and advocacy.
31
The IMF’s M-Power Initiative targets educational programs and resources towards African American communities who are twice as likely to be diagnosed with MM and more likely to experience delayed diagnosis and delayed treatment initiation.
31
M-Power educational efforts are designed to engage both the community audiences and PCPs in improving all aspects of MM care including timely diagnosis.
Screening for MM . Screening tests for breast, cervical, colorectal, and lung cancer have resulted in earlier detection, treatment and reduced mortality.
32
Screening for MM is not currently recommended, based on our incomplete understanding of the benefits and harms that screening present.
33
Recommendations for screening will require a firmer understanding of the benefits and harms, and our ability to identify the population for whom screening is most likely to be beneficial. The iStopMM study (Iceland Screens Treats, or Prevents Multiple Myeloma) promises to answer many of these questions. 33 , 34 This MM screening study recruited the entire adult population of Iceland and has enrolled more than 80,000 participants (54% of the eligible population) and results from this study are eagerly awaited. 33 , 34
Machine learning/AI.
There are increasing calls to leverage machine learning and artificial intelligence to enhance MM research and clinical practice, from identifying novel treatment targets, to estimating prognosis, to improving our ability to make earlier diagnoses. 35 - 37 A team based in China has explored using routinely collected laboratory data to train machine learning models for the early detection of MM with encouraging results.
38
Other types of readily available clinical data may help to improve diagnostic prediction, including health care utilization patterns, and the presence of diagnostic billing codes associated with MM signs and symptoms. These types of tools hold promise for solving one of the most challenging aspects of MM diagnosis; helping PCPs identify patients appropriate for more targeted MM diagnostics, (i.e., SPEP w/IFE and sFLC).
36
Although our sample was relatively diverse, most participants were recruited from a single academic institution in the Southeastern United States. Therefore, our findings may not reflect the experiences of individuals diagnosed with MM in other regions or care settings. Our interviews provide rich, in-depth accounts of MM diagnostic journeys; however, the small sample size limits the generalizability of these findings. Because participants were asked to recall past experiences within a complex and fragmented health care system, their accounts may be influenced by memory limitations, reinterpretation in hindsight, and social desirability bias. Despite these limitations our study sheds important light on the barriers and facilitators to receiving a MM diagnosis.
Supplementary Material
Supplemental Material for Multiple Myeloma: Insights Into a Challenging Diagnostic Journey by Matthew R. LeBlanc, Melissa Luna, Kalin Bennington, Staci Keene, Allison O. Taylor, Susana Barroso, Thomas Goode, Tony Newberne, Valarie Traynham, Sascha A. Tuchman, Samuel M. Rubinstein, Eben I. Lichtman, Joseph Mikhael, Atinuke G. Oyinbo, Saif Al-Amin, Osborn O. Ansah, Mark A. Fiala, Lisa N. Mansfield in Journal of Primary Care & Community Health.
Supplemental Material for Multiple Myeloma: Insights Into a Challenging Diagnostic Journey by Matthew R. LeBlanc, Melissa Luna, Kalin Bennington, Staci Keene, Allison O. Taylor, Susana Barroso, Thomas Goode, Tony Newberne, Valarie Traynham, Sascha A. Tuchman, Samuel M. Rubinstein, Eben I. Lichtman, Joseph Mikhael, Atinuke G. Oyinbo, Saif Al-Amin, Osborn O. Ansah, Mark A. Fiala, Lisa N. Mansfield in Journal of Primary Care & Community Health.